Current status of 5α-reductase inhibitors in the treatment of benign hyperplasia of prostate

Kumar, Vijay; Wahane, V.D.

doi:10.4103/0019-5359.40582

Cited by 17 publications

(21 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dutasteride was found to improve urinary flow rate, decrease the risk of acute urinary retention and need for surgery by reducing the size of enlarged prostate. Improved efficacy of dutasteride (0.5 mg/day) over finasteride (5 mg/day) in terms of symptom score, maximal urinary flow rate and quality of life had also been published by Kumar, et al [32].…”

Section: Dutasteridementioning

confidence: 84%

“…It is a competitive inhibitor of 5α-reductase type 2 with 10 fold high affinity than type 1 and forms a stable complex with enzyme ( Figure 4). It has been reported that at clinical doses of 5 mg/day in human, it decreases the prostate DHT level by 70-90%, thus resulting in decreased prostate volume or size and improved urinary flow rate in BPH patients [32]. It has neither androgenic, antiandrogenic, other hormone related properties, nor it interferes with the binding of T or DHT to the AR [33].…”

Section: α-Reductase Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

5α- Reductase Inhibitors in Prostate Cancer: An Overview

Passi¹

2017

Austin J Cancer Clin Res

View full text Add to dashboard Cite

Prostate cancer is the noncutaneous malignancy of the prostate gland in elderly men. Steroid 5α-reductase (5AR) enzyme dictates the cellular availability of dihydrotestosterone to prostatic epithelial cells and consequently modulates its growth. Excessive production of DHT has been implicated in the pathogenesis of Prostate cancer. Finasteride and Dutasteride, clinically available 5AR inhibitors may play an important role in the prevention and treatment of prostate cancer by blocking peripheral conversion of T into DHT. This article gives a brief account of biology of prostate, rationale and efficacy of 5AR inhibitors in prostate cancer management and their associated controversies.

show abstract

Section: Dutasteridementioning

confidence: 84%

Section: α-Reductase Inhibitorsmentioning

confidence: 99%

5α- Reductase Inhibitors in Prostate Cancer: An Overview

Passi¹

2017

Austin J Cancer Clin Res

View full text Add to dashboard Cite

show abstract

“…It has been reported that at clinical doses of 5 mg/day in human beings, it decreases the prostate DHT level by 70 to 90%, thus resulting in decreased prostate volume or size and improved urinary flow rate. [2930] It has neither androgenic, antiandrogenic, other hormone related properties, nor it interferes with the binding of T or DHT to the androgen receptor. [31] The investigators found significant improvement in finasteride-treated groups in term of increased flow rates and decreased prostate-specific antigen level.…”

Section: Androgen Deprivation Therapymentioning

confidence: 99%

“…[30] It was approved by US FDA in 2002 for the symptomatic treatment of BPH. Unlike finasteride, dutasteride has been reported to be a nonselective competitive inhibitor of both 5α-reductase type 1 and 5α-reductase type 2 isozymes.…”

Section: Androgen Deprivation Therapymentioning

confidence: 99%

Benign prostatic hyperplasia: An overview of existing treatment

Dhingra

Bhagwat²

2011

Indian J Pharmacol

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) is the most common condition in aging men, associated with lower urinary tract symptoms (LUTS). A better understanding of the prostate physiology, function, and pathogenesis has led to the development of promising agents, useful in the management of LUTS in men. The specific approach used to treat BPH depends upon number of factors like age, prostrate size, weight, prostate-specific antigen level, and severity of the symptoms. 5α-reductase inhibitors decrease the production of dihydrotestosterone within the prostate, which results in decreased prostate volume, increased peak urinary flow rate, improvement of symptoms, decreased risk of acute urinary retention, and need for surgical intervention. α1-adrenergic receptor (α1-AR) antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. Clinical efficacy of either 5α-reductase inhibitor or α1-AR antagonist has been further improved by using combination therapy; however, long-term outcomes are still awaited. Many more potential new therapies are under development that may improve the treatment of BPH. This article gives a brief account of rationale and efficacy of different treatment options presently available in the management of BPH.

show abstract

“…[3] This fact was further confirm with the development of 5α reductase inhibitors, namely finasteride and dutasteride, which when given to BPH patients significantly reduced prostate size and DHT level in the prostate. [4][5][6] However, this conventional treatment for BPH is restricted because of associated side effects, such as erectile dysfunction, loss of libido, dizziness, gynaecomastia and upper respiratory tract infection. [7] Plants are important sources of therapeutic drugs and play a significant role of in the survival of the tribal and ethnic communities.…”

Section: Introductionmentioning

confidence: 99%

Aqueous Methanolic Bark Extract of Oroxylum indicum Inhibited Testosterone induced Prostate Hyperplasia in Rat

Bharali¹,

Chetry²

2014

Phcog J.

View full text Add to dashboard Cite

Oroxylum indicum is a frequently reported traditional medicinal plant known to possess antiproliferative and antitumor activity. The present study investigated the effect of crude methanolic bark extract of Oroxylum indicum on testosterone induced benign prostate hyperplasia (BPH) in rat. Adult male rats were given either corn oil or testosterone dissolved in corn oil and testosterone with aqueous methanolic bark extracts of Oroxylum indicum (10, 50 and 100 mg/kg/day) for 14 days. The inhibitory effect of Oroxylum indicum on testosterone induced hyperplasia was evaluated by prostatic index and histopathological examination. Serum marker of liver injury (alanine aminotransferase, ALT and aspartate aminotransferase, AST) and liver histopathological examination were also conducted. Compared with testosterone induced BPH model group, Oroxylum indicum extract treated groups exhibited significant reduction in the prostatic index. Oroxylum indicum treated group also exhibited reduced hyperplasia of prostatic epithelium likewise finasteride treated group. Aqueous methanolic extract of Oroxylum indicum significantly inhibited testosterone induced prostate hyperplasia thus indicated the presence of efficient ingredients which can be used for the treatment of BPH.

show abstract

Current status of 5α-reductase inhibitors in the treatment of benign hyperplasia of prostate

Cited by 17 publications

References 42 publications

5α- Reductase Inhibitors in Prostate Cancer: An Overview

5α- Reductase Inhibitors in Prostate Cancer: An Overview

Benign prostatic hyperplasia: An overview of existing treatment

Aqueous Methanolic Bark Extract of Oroxylum indicum Inhibited Testosterone induced Prostate Hyperplasia in Rat

Contact Info

Product

Resources

About